Grand Brilliance Group Holdings Limited

SEHK:8372 Stock Report

Mkt Cap: HK$59.2m

We’ve recently updated our valuation analysis.

Grand Brilliance Group Holdings Valuation

Is 8372 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 0/6

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 8372?

Other financial metrics that can be useful for relative valuation.

8372 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.04x
Enterprise Value/EBITDA0.7x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does 8372's PE Ratio compare to its peers?

The above table shows the PE ratio for 8372 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average39.7x
1110 Kingworld Medicines Group
2289 Charmacy Pharmaceutical
1298 Yunnan Energy International
6833 Sinco Pharmaceuticals Holdings
8372 Grand Brilliance Group Holdings

Price to Earnings Ratio vs Industry

How does 8372's PE Ratio compare vs other companies in the HK Healthcare Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a23.9%
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a23.9%
No more companies

Price to Earnings Ratio vs Fair Ratio

What is 8372's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

8372 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio17.4x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 8372's Price-To-Earnings Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of 8372 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Discover undervalued companies